Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Maxel Pharma Oy
OY
Active
Y-tunnus 2276780-0
Eerikinkartanontie 286, 02880
Veikkola
Business and other management consultancy activities
·
NACE 7020
Est. 2009 · 16 years old
— employees
Share
Finland
/
Companies
/
Business and other management consultancy activities
/
Maxel Pharma Oy
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
EUR millions
0M
1M
1M
2M
2M
2M
2020
2M
2021
2M
2022
0M
2023
2M
2024
EBITDA
EUR millions
0M
-0M
-1M
-1M
-1M
0M
2020
0M
0%
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
Income statement
EUR thousands
Item
2020
2021
2022
2023
2024
Revenue
1 682
1 799
1 905
—
2 142
Staff expenses
−255
−358
−337
—
−498
EBITDA
175
212
2
—
381
Depreciation & amort.
−1
−1
−1
—
−0
EBIT
174
211
1
363
381
Net financials
−0
−0
−0
—
2
Profit before tax
174
211
1
—
383
Tax
35
42
−0
73
77
Net profit
139
169
1
290
306
Balance sheet
EUR thousands
Item
2020
2021
2022
2023
2024
Total assets
603
751
643
996
1 144
Equity
462
594
548
794
1 037
Long-term debt
—
—
—
0
0
Short-term debt
142
157
95
202
108
Total debt
142
157
95
202
108
Financial ratios
5-year trend
EBITDA margin
17.8%
This company
15.8%
Market median
+13% vs market
2020
2024
Equity ratio
90.6%
This company
38.2%
Market median
+137% vs market
2020
2024
Return on equity
29.5%
This company
18.4%
Market median
+60% vs market
2020
2024
Net profit margin
14.3%
This company
8.1%
Market median
+77% vs market
2020
2024
Asset turnover
1.87×
This company
1.12×
Market median
+67% vs market
2020
2024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
View
PDF
More on Maxel Pharma Oy
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
